Equillium, Inc. NASDAQ:EQ

Founder-led company

Equillium stock price today

$1.27
+0.57
+83%
Financial Health
0
1
2
3
4
5
6
7
8
9

Equillium stock price monthly change

-17.61%
month

Equillium stock price quarterly change

-17.61%
quarter

Equillium stock price yearly change

+6.59%
year

Equillium key metrics

Market Cap
21.43M
Enterprise value
N/A
P/E
-0.4
EV/Sales
-2.28
EV/EBITDA
0.58
Price/Sales
1.57
Price/Book
0.77
PEG ratio
0.01
EPS
-0.35
Revenue
37.89M
EBITDA
-12.15M
Income
-12.12M
Revenue Q/Q
20.38%
Revenue Y/Y
53.80%
Profit margin
-396.14%
Oper. margin
-247.65%
Gross margin
100%
EBIT margin
-247.65%
EBITDA margin
-32.07%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Equillium stock price history

Equillium stock forecast

Equillium financial statements

Equillium, Inc. (NASDAQ:EQ): Profit margin
Jun 2023 9.12M -3.34M -36.64%
Sep 2023 8.87M -3.71M -41.83%
Dec 2023 9.21M -2.34M -25.43%
Mar 2024 10.68M -2.73M -25.58%
Equillium, Inc. (NASDAQ:EQ): Analyst Estimates
Mar 2024 10.68M -2.73M -25.58%
Sep 2025 13.61M -7.03M -51.65%
Oct 2025 14.93M -7.05M -47.2%
Dec 2025 15.79M -7.40M -46.87%
  • Analysts Price target

  • Financials & Ratios estimates

Equillium, Inc. (NASDAQ:EQ): Debt to assets
Jun 2023 58764000 31.78M 54.09%
Sep 2023 55225000 31.11M 56.35%
Dec 2023 50530000 27.95M 55.33%
Mar 2024 43597000 22.50M 51.62%
Equillium, Inc. (NASDAQ:EQ): Cash Flow
Jun 2023 -6.21M 15M -7.61M
Sep 2023 -1.90M 10.98M -260K
Dec 2023 -5.66M -5.56M 79K
Mar 2024 -8.8M -2.83M 0

Equillium alternative data

Equillium, Inc. (NASDAQ:EQ): Employee count
Aug 2023 37
Sep 2023 47
Oct 2023 47
Nov 2023 47
Dec 2023 45
Jan 2024 45
Feb 2024 45
Mar 2024 44
Apr 2024 44
May 2024 44
Jun 2024 44
Jul 2024 44

Equillium other data

22.49% -13.07%
of EQ is owned by hedge funds
7.58M -4.62M
shares is hold by hedge funds

Equillium, Inc. (NASDAQ:EQ): Insider trades (number of shares)
Period Buy Sel
Sep 2021 0 8000
Oct 2021 0 2467
Nov 2021 0 11434
Dec 2021 0 5000
Apr 2022 0 8000
Jun 2022 0 5000
Aug 2022 0 7000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
KEYES JASON A officer: Chief Financial Officer
Common Stock 7,000 $2.83 $19,810
Sale
KEYES JASON A officer: Chief Financial Officer
Common Stock 5,000 $2.52 $12,600
Sale
KEYES JASON A officer: Chief Financial Officer
Common Stock 8,000 $3.18 $25,440
Sale
KEYES JASON A officer: Chief Financial Officer
Common Stock 5,000 $5.08 $25,400
Option
ZEDELMAYER CHRISTINE officer: Sr. Vice President and..
Employee Stock Option 23,334 $2.45 $57,168
Sale
ZEDELMAYER CHRISTINE officer: Sr. Vice President and..
Common Stock 11,434 $5.49 $62,715
Option
ZEDELMAYER CHRISTINE officer: Sr. Vice President and..
Common Stock 23,334 $2.45 $57,168
Option
CONNELLY STEPHEN director, officer.. Employee Stock Option (right to buy) 2,467 $2.8 $6,908
Option
CONNELLY STEPHEN director, officer.. Common Stock 8,092 $3.78 $30,547
Sale
CONNELLY STEPHEN director, officer.. Common Stock 2,467 $7.01 $17,289
Insider Compensation
Dr. Krishna R. Polu (1973) Consultant $612,000
Dr. Stephen Connelly Ph.D. (1982) Chief Scientific Officer & Director $516,610
Mr. Bruce D. Steel C.F.A. (1966) Co-Founder, Pres, Chief Executive Officer & Director
$414,420
Mr. Daniel Mark Bradbury (1961) Executive Chairman $92,190
Wednesday, 13 November 2024
businesswire.com
Wednesday, 6 November 2024
zacks.com
Thursday, 8 August 2024
zacks.com
Thursday, 18 July 2024
businesswire.com
Wednesday, 12 June 2024
businesswire.com
Wednesday, 5 June 2024
businesswire.com
Tuesday, 4 June 2024
businesswire.com
Wednesday, 29 May 2024
businesswire.com
Tuesday, 14 May 2024
businesswire.com
Thursday, 9 May 2024
Zacks Investment Research
Monday, 1 April 2024
Zacks Investment Research
Monday, 25 March 2024
Zacks Investment Research
Friday, 22 March 2024
Business Wire
Friday, 1 March 2024
Zacks Investment Research
Friday, 23 February 2024
Zacks Investment Research
Monday, 2 October 2023
Business Wire
Wednesday, 9 August 2023
Zacks Investment Research
Thursday, 11 May 2023
Zacks Investment Research
Tuesday, 8 November 2022
Business Wire
Tuesday, 27 September 2022
InvestorPlace
Market Watch
Wednesday, 31 August 2022
Business Wire
Tuesday, 29 March 2022
Zacks Investment Research
Wednesday, 9 February 2022
Business Wire
Tuesday, 4 January 2022
Benzinga
Wednesday, 22 September 2021
Business Wire
  • What's the price of Equillium stock today?

    One share of Equillium stock can currently be purchased for approximately $1.27.

  • When is Equillium's next earnings date?

    Unfortunately, Equillium's (EQ) next earnings date is currently unknown.

  • Does Equillium pay dividends?

    No, Equillium does not pay dividends.

  • How much money does Equillium make?

    Equillium has a market capitalization of 21.43M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 128.97% to 36.08M US dollars.

  • What is Equillium's stock symbol?

    Equillium, Inc. is traded on the NASDAQ under the ticker symbol "EQ".

  • What is Equillium's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Equillium?

    Shares of Equillium can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Equillium's key executives?

    Equillium's management team includes the following people:

    • Dr. Krishna R. Polu Consultant(age: 52, pay: $612,000)
    • Dr. Stephen Connelly Ph.D. Chief Scientific Officer & Director(age: 43, pay: $516,610)
    • Mr. Bruce D. Steel C.F.A. Co-Founder, Pres, Chief Executive Officer & Director(age: 59, pay: $414,420)
    • Mr. Daniel Mark Bradbury Executive Chairman(age: 64, pay: $92,190)
  • Is Equillium founder-led company?

    Yes, Equillium is a company led by its founder Mr. Bruce D. Steel C.F.A..

  • How many employees does Equillium have?

    As Jul 2024, Equillium employs 44 workers.

  • When Equillium went public?

    Equillium, Inc. is publicly traded company for more then 6 years since IPO on 12 Oct 2018.

  • What is Equillium's official website?

    The official website for Equillium is equilliumbio.com.

  • Where are Equillium's headquarters?

    Equillium is headquartered at 2223 Avenida De La Playa, La Jolla, CA.

  • How can i contact Equillium?

    Equillium's mailing address is 2223 Avenida De La Playa, La Jolla, CA and company can be reached via phone at 858 412 5302.

Equillium company profile:

Equillium, Inc.

equilliumbio.com
Exchange:

NASDAQ

Full time employees:

45

Industry:

Biotechnology

Sector:

Healthcare

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

2223 Avenida De La Playa
La Jolla, CA 92037

CIK: 0001746466
ISIN: US29446K1060
CUSIP: 29446K106